CLAIMS

1. Use of a cAMP modulator for preparing a composition intended for the prevention or treatment of peripheral neuropathies.

2. Use according to claim 1, characterized in that the composition is intended for the prevention or treatment of demyelinating peripheral neuropathies.

3. Use according to any one of claims 1 or 2, characterized in that the cAMP modulator is preferably an inhibitor of said cAMP.

4. Use according to any one of claims 1, 2 or 3, characterized in that the cAMP inhibitor is vitamin C or a derivative thereof.

5. Use according to any one of claims 1 to 4, characterized in that the composition is intended for the prevention or treatment of hereditary peripheral neuropathies.

6. Use according to claim 5, characterized in that the composition is intended for the prevention or treatment of Charcot-Marie-Tooth disease.

7. Use according to claim 6, characterized in that Charcot-Marie-Tooth disease corresponds to type 1 (CMT1) of said disease.

8. Use according to any one of claims 1 to 4, characterized in that the composition is intended for the prevention or treatment of non-hereditary peripheral neuropathies.

9. Use according to any one of claims 4 to 8, characterized in that the vitamin C is selected in the group consisting of natural vitamin C, synthetic vitamin C and a mixture thereof.

10. Use according to any one of claims 4 to 9, characterized in that the vitamin C derivative is selected in the group consisting of vitamin C salts and esters.

11. Use according to claim 10, characterized in that the derivative is selected in the group consisting of ascorbyl palmitate, dipalmitate L-ascorbate and their mixture or in the group consisting of glycosylated, mannosylated, fructosylated, fucosylated, galactosylated, N-acetylglucosaminated, N-acetylmuramic derivatives of ascorbic acid and their mixtures, preferably ascorbyl-2 glucoside, 2-O-alpha-D-glucopyranosyl ascorbic acid or 6-O-beta-D-galactopyranosyl L-ascorbic acid.

12. Use according to claim 10, characterized in that the derivative is selected in the group consisting of the metal salts of phosphorylated ascorbic acid, in particular the alkaline metal ascorbyl phosphates, the alkaline earth metal ascorbyl phosphates and the transition metal ascorbyl phosphates, preferably magnesium ascorbyl phosphate or else the ascorbyl sulfates.

13. Use according to any one of the previous claims, characterized in that the composition regulates cAMP expression.

14. Use according to any one of the previous claims, characterized in that the composition reduces cAMP expression.

15. Use according to any one of the previous claims, characterized in that the composition regulates the expression of the PMP22 protein.

16. Use according to claim 15, characterized in that the composition reduces the expression of the PMP22 protein.

17. Method for preparing a composition for treating peripheral neuropathies characterized in that the composition comprises as active substance a

cAMP modulator that can be assimilated by humans or animals, in association with a pharmaceutically acceptable vehicle.

18. Method according to claim 17, characterized in that the cAMP modulator is an inhibitor of said cAMP.

19. Method according to claim 18, characterized in that the cAMP inhibitor is ascorbic acid or a derivative thereof that can be assimilated by humans or animals.

20. Method according to claim 19, characterized in that the vitamin C is selected in the group consisting of natural vitamin C, synthetic vitamin C and a mixture thereof.

21. Method according to claim 20, characterized in that the composition comprises 250 milligrams to 6 grams of vitamin C or a vitamin C derivative.

22. Kit intended for implementing a method according to any one of claims 17 to 21.